NCT06460987View on ClinicalTrials.gov

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

CompletedOBSERVATIONAL
Enrollment

245

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
FinerenoneIgA NephropathyProteinuriaSafety Issues
Interventions
DRUG

Finerenone

Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels

DRUG

RAS inhibitor

Receive RAS inhibitor treatment as specified in the KDIGO guidelines

DRUG

Immune Suppressant

Receive immune suppressant treatment as specified in the KDIGO guidelines

Trial Locations (1)

Unknown

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy, Yiwu

All Listed Sponsors
lead

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

OTHER